PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn

NCT04256993 · clinicaltrials.gov ↗

COMPLETED

Status

1434

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)
DRUG: Other standard care

Sponsor

Bayer